Capital Impact Advisors LLC Has $40.91 Million Stake in Natera, Inc. $NTRA

Capital Impact Advisors LLC grew its stake in Natera, Inc. (NASDAQ:NTRA) by 174.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 178,567 shares of the medical research company’s stock after purchasing an additional 113,508 shares during the period. Natera comprises about 3.2% of Capital Impact Advisors LLC’s investment portfolio, making the stock its 12th biggest position. Capital Impact Advisors LLC’s holdings in Natera were worth $40,908,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in NTRA. Integrated Wealth Concepts LLC lifted its holdings in shares of Natera by 6.6% during the 1st quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company’s stock worth $221,000 after acquiring an additional 96 shares during the period. NewEdge Advisors LLC lifted its holdings in shares of Natera by 68.3% during the 1st quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company’s stock worth $644,000 after acquiring an additional 1,847 shares during the period. Focus Partners Wealth lifted its holdings in shares of Natera by 8.6% during the 1st quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company’s stock worth $847,000 after acquiring an additional 474 shares during the period. Sivia Capital Partners LLC bought a new position in shares of Natera during the 2nd quarter worth about $298,000. Finally, WINTON GROUP Ltd bought a new position in shares of Natera during the 2nd quarter worth about $558,000. 99.90% of the stock is owned by institutional investors.

Insider Activity

In related news, Director Roelof Botha sold 78,000 shares of Natera stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $220.31, for a total transaction of $17,184,180.00. Following the completion of the transaction, the director directly owned 1,076,198 shares of the company’s stock, valued at $237,097,181.38. This trade represents a 6.76% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Gail Boxer Marcus sold 11,000 shares of Natera stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $217.21, for a total transaction of $2,389,310.00. Following the transaction, the director directly owned 6,183 shares of the company’s stock, valued at $1,343,009.43. This represents a 64.02% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 162,342 shares of company stock worth $35,283,396 over the last ninety days. Corporate insiders own 5.05% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. Evercore reaffirmed an “outperform” rating and set a $270.00 price objective on shares of Natera in a report on Friday, May 8th. Wolfe Research assumed coverage on shares of Natera in a report on Tuesday, June 2nd. They set an “outperform” rating and a $260.00 price objective for the company. Wells Fargo & Company raised their price objective on shares of Natera from $215.00 to $220.00 and gave the stock an “equal weight” rating in a report on Friday, May 8th. JPMorgan Chase & Co. raised their price objective on shares of Natera from $260.00 to $265.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. Finally, BTIG Research reduced their price objective on shares of Natera from $260.00 to $250.00 and set a “buy” rating for the company in a report on Monday, May 11th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $256.53.

Natera Stock Up 2.9%

Shares of NTRA stock opened at $226.44 on Thursday. Natera, Inc. has a 12-month low of $131.81 and a 12-month high of $256.36. The company has a market capitalization of $32.43 billion, a P/E ratio of -138.92 and a beta of 1.56. The firm has a 50-day moving average price of $207.35 and a 200 day moving average price of $215.50.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.